Clustering patients by depression symptoms may predict treatment outcomes for major depressive disorder: Patient-level meta-analysis of venlafaxine extended release trials

被引：0

作者：

Kato, M. ^{[1
]}

Asami, Y. ^{[2
]}

Boucher, M. ^{[3
,4
]}

Pappadopulos, E. ^{[5
]}

Prieto Lopez, R. ^{[6
]}

Wang, X. ^{[7
]}

Wajsbrot, D. ^{[8
]}

机构：

[1] Kansai Med Univ, Dept Neuropsychiat, Osaka, Japan

[2] Pfizer Japan Inc, Med Affairs CNS, Tokyo, Japan

[3] Pfizer Canada Inc, Montreal, PQ, Canada

[4] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada

[5] Pfizer Inc, Med Affairs, New York, NY USA

[6] Pfizer GEP SLU, Res Dev & Med, Madrid, Spain

[7] Syneos Hlth Inc, Clin Stat, Raleigh, NC USA

[8] Pfizer Inc, Clin Stat Grp, Pfizer Essential Hlth, New York, NY USA

来源：

关键词：

D O I：

10.1016/j.euroneuro.2019.09.594

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P.610

引用

页码：S417 / S418

页数：2